“Over the years, the nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The global nuclear medicine/radiopharmaceuticals market is growing due to the increasing number of radioisotope approvals for different clinical indications. Tc-99m and F-18 are estimated to be the highest contributors to the nuclear medicine/radiopharmaceuticals diagnostics market; whereas, Ra-223, I-131, and Y-90 are estimated to be the highest contributors for the nuclear medicine/radiopharmaceuticals therapeutics market in 2015.
In 2015, the diagnostics segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals market, by type; the SPECT segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals diagnostics market; whereas, the beta emitters segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals therapeutics market.
In 2015, North America accounted for the largest share of the nuclear medicine/radiopharmaceuticals market, followed by Asia-Pacific, Europe, and the Rest of the World (RoW). In the coming years, the Asia-Pacific region is expected to witness the highest growth rate for the nuclear medicine/radiopharmaceuticals market, with an emphasis on India, China, Japan, and Australia. These countries are expected to be lucrative markets for the manufacturers of radiopharmaceuticals.
The global nuclear medicine/radiopharmaceuticals market witnesses high-competitive intensity as there are several large and small firms with similar product offerings. These companies adopt various strategies (agreements, contracts, partnerships, expansions, acquisitions, market development, new product launches, marketing and promotional activities, technological enhancements, and website launches) to increase their market shares and to establish a strong foothold in the global market.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the nuclear medicine/radiopharmaceuticals market. The report analyzes the nuclear medicine/radiopharmaceuticals market by type, and application, and procedural volume
• Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the nuclear medicine/radiopharmaceuticals market
• Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various nuclear medicine/radiopharmaceuticals technologies across regions
• Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the nuclear medicine/radiopharmaceuticals market
• Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the nuclear medicine/radiopharmaceuticals market
”
“TABLE OF CONTENTS
1 INTRODUCTION 18
1.1 OBJECTIVES OF STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY 20
1.5 LIMITATIONS 20
1.6 STAKEHOLDERS 20
2 RESEARCH METHODOLOGY 21
2.1 RESEARCH METHODOLOGY STEPS 21
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 22
2.2.1 SECONDARY RESEARCH 22
2.2.2 PRIMARY RESEARCH 23
2.2.3 KEY INDUSTRY INSIGHTS 23
2.3 KEY DATA FROM PRIMARY SOURCES 24
2.4 KEY INSIGHTS FROM PRIMARY SOURCES 25
2.5 MARKET SIZE ESTIMATION METHODOLOGY 25
2.6 RESEARCH DESIGN 27
2.7 MARKET DATA VALIDATION AND TRIANGULATION 28
2.8 ASSUMPTIONS FOR THE STUDY 28
3 EXECUTIVE SUMMARY 29
3.1 INTRODUCTION 29
3.2 CURRENT SCENARIO 30
3.3 FUTURE OUTLOOK 30
3.4 CONCLUSION 32
4 PREMIUM INSIGHTS 33
4.1 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 33
4.2 SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTICS MARKET, BY REGION AND APPLICATION 34
4.3 REGIONAL SNAPSHOT OF THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 35
4.4 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE (2015 VS. 2020) 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 38
5.2 MARKET DYNAMICS 38
5.2.1 DRIVERS 39
5.2.1.1 Increasing preference for SPECT and PET scans 39
5.2.1.2 Advances in radiotracers 39
5.2.1.3 Alpha radio immunotherapy-based targeted cancer treatment 39
5.2.1.4 Increasing incidence of cancer and cardiac ailments 40
5.2.2 RESTRAINTS 41
5.2.2.1 Shorter half-life of radiopharmaceuticals restricts its usage 41
5.2.2.2 Stringent regulatory and GMP guidelines 41
5.2.2.3 Competition from conventional diagnostic procedures 42
5.2.3 OPPORTUNITIES 43
5.2.3.1 Potential radioisotopes in the pipeline 43
5.2.3.2 High demand in emerging markets 43
5.2.3.3 Neurological applications 43
5.2.4 THREAT 44
5.2.4.1 Shutdown of nuclear reactors 44
6 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE 46
6.1 INTRODUCTION 47
6.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 49
6.2.1 SPECT RADIOPHARMACEUTICALS 51
6.2.1.1 Technetium-99m (Tc-99m) 52
6.2.1.2 Thallium-201 (Tl-201) 53
6.2.1.3 Gallium-67 (Ga-67) 54
6.2.1.4 Iodine (I-123) 55
6.2.1.5 Others 55
6.2.2 PET RADIOPHARMACEUTICALS 56
6.2.2.1 Fluorine-18 (F-18) 58
6.2.2.2 Rubidium-82 (Rb-82) 59
6.2.2.3 Others 59
6.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 60
6.3.1 BETA EMITTERS 62
6.3.1.1 Iodine-131 (I-131) 64
6.3.1.2 Yttrium-90 (Y-90) 65
6.3.1.3 Samarium-153 (Sm-153) 65
6.3.1.4 Rhenium-186 (Re-186) 66
6.3.1.5 Lutetium-177 (Lu-177) 67
6.3.1.6 Others 67
6.3.2 ALPHA EMITTERS 68
6.3.2.1 Radium-223 (Ra-223) 69
6.3.3 BRACHYTHERAPY 70
6.3.3.1 Cesium-131 72
6.3.3.2 Iodine-125 72
6.3.3.3 Palladium-103 73
6.3.3.4 Iridium-192 74
6.3.3.5 Others 75
7 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME 76
7.1 INTRODUCTION 77
7.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 78
7.2.1 SPECT RADIOPHARMACEUTICALS 79
7.2.2 PET RADIOPHARMACEUTICALS 80
7.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 81
7.3.1 BETA EMITTERS 82
7.3.2 ALPHA EMITTERS 83
7.3.3 BRACHYTHERAPY 84
8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION 85
8.1 INTRODUCTION 86
8.2 DIAGNOSTIC APPLICATIONS 86
8.2.1 SPECT APPLICATIONS 86
8.2.1.1 Cardiology 89
8.2.1.2 Lymphoma 90
8.2.1.3 Neurology 91
8.2.1.4 Thyroid 92
8.2.1.5 Other Diagnostic Applications 93
8.2.2 PET APPLICATIONS 94
8.2.2.1 Oncology 96
8.2.2.2 Cardiology 97
8.2.2.3 Neurology 98
8.2.2.4 Other PET Applications 99
8.3 THERAPEUTIC APPLICATIONS 99
8.3.1 THYROID 102
8.3.2 BONE METASTASIS 103
8.3.3 LYMPHOMA 104
8.3.4 ENDOCRINE TUMORS 105
8.3.5 OTHER THERAPEUTIC APPLICATIONS 105
9 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY REGION 107
9.1 INTRODUCTION 108
9.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 109
9.2.1 NORTH AMERICA 110
9.2.1.1 DEVELOPMENT OF MO-99 PRODUCTION FACILITIES IN THE U.S. 111
9.2.1.2 FDA APPROVALS OF NEW RADIOPHARMACEUTICALS 111
9.2.1.3 EXTENSION OF OPERATIONS IN THE CANADIAN NATIONAL RESEARCH UNIVERSAL (NRU) REACTOR 111
9.2.1.4 DEVELOPMENT OF ALTERNATIVE MEDICAL ISOTOPE TECHNOLOGIES IN CANADA 111
9.2.2 EUROPE 114
9.2.2.1 INCREASING ACCEPTABILITY OF 18F-FDG PET-CT IN THE U.K. 115
9.2.2.2 SHUTDOWN OF FRENCH NUCLEAR REACTOR 115
9.2.2.3 NEW IRRADIATION FACILITY IN GERMANY 116
9.2.3 ASIA-PACIFIC 119
9.2.3.1 INTRODUCTION OF NEW COST-EFFECTIVE TC-99 GENERATORS IN INDIA 120
9.2.3.2 HIGH INCIDENCE OF CANCER AND CARDIOVASCULAR DISEASE IN CHINA 120
9.2.3.3 INCREASING MO-99 PRODUCTION IN AUSTRALIA 120
9.2.3.4 INITIATIVES TO PROMOTE HEALTH IN ASIA-PACIFIC 120
9.2.4 REST OF THE WORLD 124
9.2.4.1 DEVELOPMENT OF MULTIPURPOSE RESEARCH REACTOR IN BRAZIL 125
9.2.4.2 ARGENTINA’S INCREASING IRRADIATION CAPACITY 125
9.2.4.3 CONVERSION OF THE SAFARI 1 REACTOR, FROM HEU-BASED MO-99 PRODUCTION TO LEU 125
9.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 128
9.3.1 NORTH AMERICA 128
9.3.1.1 FDA approval for alpha emitters in the U.S. 129
9.3.1.2 Therapeutic nuclear medicine, an alternative choice of treatment in oncology 130
9.3.1.3 Increase in the incidence of thyroid cancer 130
9.3.1.4 Expertise in isotope production 130
9.3.1.5 Government initiatives 130
9.3.1.6 High incidence of cancer 131
9.3.2 EUROPE 133
9.3.2.1 Increasing awareness of radioisotope therapy in the U.K. 134
9.3.2.2 Adverse reactions to radiopharmaceuticals in France 134
9.3.2.3 Radionuklidtherapeutika—research program conducted in Germany 135
9.3.2.4 Russia, an upcoming country for radionuclide therapy 135
9.3.3 ASIA-PACIFIC 137
9.3.3.1 Increased production of radiopharmaceuticals for therapeutic purposes in India 139
9.3.3.2 Aging population and increasing cancer incidence 139
9.3.3.3 Approval of radium (223Ra) dichloride by the therapeutic goods administration (TGA) 139
9.3.4 REST OF THE WORLD(ROW) 142
9.3.4.1 Growing aging population 143
9.3.4.2 Increase in cancer incidences 143
10 COMPETITIVE LANDSCAPE 146
10.1 OVERVIEW 146
10.2 MARKET SHARE ANALYSIS 146
10.2.1 INTRODUCTION 146
10.2.2 CARDINAL HEALTH, INC. 147
10.2.3 MALLINCKRODT PLC 148
10.2.4 GE HEALTHCARE 149
10.2.5 LANTHEUS MEDICAL IMAGING, INC. 150
10.2.6 BAYER HEALTHCARE 151
10.3 COMPETITIVE SITUATION AND TRENDS 153
10.3.1 INTRODUCTION 153
10.3.2 AGREEMENTS, CONTRACTS, AND PARTNERSHIPS 154
10.3.3 ACQUISITIONS 155
10.3.4 MARKET DEVELOPMENT 156
10.3.5 EXPANSION 156
10.3.6 NEW PRODUCT LAUNCHES 157
10.3.7 OTHERS 158
11 COMPANY PROFILES 159
11.1 INTRODUCTION 159
11.2 CARDINAL HEALTH, INC. 160
11.3 MALLINCKRODT PLC 163
11.4 GE HEALTHCARE 165
11.5 LANTHEUS MEDICAL IMAGING, INC. 168
11.6 BAYER HEALTHCARE 170
11.7 BRACCO IMAGING S.P.A 172
11.8 ECZACIBASI-MONROL NUCLEAR PRODUCTS 174
11.9 NORDION, INC. 176
11.10 ADVANCED ACCELERATOR APPLICATIONS S.A. 178
11.11 IBA MOLECULAR IMAGING 180
*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.
12 APPENDIX 182
12.1 DISCUSSION GUIDE 182
12.2 COMPANY DEVELOPMENTS (2012–2015) 190
12.2.1 CARDINAL HEALTH, INC. 190
12.2.2 BAYER HEALTHCARE 190
12.3 AVAILABLE CUSTOMIZATIONS 191
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 191
12.5 RELATED REPORTS 192
“
“LIST OF TABLES
TABLE 1 ALPHA RADIO IMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT TO BOOST THE GROWTH OF THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 40
TABLE 2 SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS RESTRAINING THE GROWTH OF THE NUCLEAR MEDICINE MARKET 42
TABLE 3 POTENTIAL RADIOISOTOPES IN THE PIPELINE OFFER SIGNIFICANT GROWTH OPPORTUNITIES FOR THE NUCLEAR MEDICINE MARKET 44
TABLE 4 SHUTDOWN OF NUCLEAR REACTORS IS A MAJOR CHALLENGE IN THIS MARKET 45
TABLE 5 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 48
TABLE 6 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR DIAGNOSTIC SEGMENT, BY REGION, 2013-2020 ($MILLION) 49
TABLE 7 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR DIAGNOSTIC ISOTOPES, BY TYPE, 2013-2020 ($MILLION) 50
TABLE 8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT ISOTOPES, BY REGION, 2013-2020 ($MILLION) 51
TABLE 9 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY ISOTOPE TYPE, 2013-2020 ($MILLION) 52
TABLE 10 GLOBAL SPECT MARKET SIZE FOR TECHNETIUM-99M ISOTOPES, BY REGION, 2013-2020 ($MILLION) 53
TABLE 11 GLOBAL SPECT MARKET SIZE FOR THALLIUM-201 ISOTOPES, BY REGION,
2013-2020 ($MILLION) 53
TABLE 12 GLOBAL SPECT MARKET SIZE FOR GALLIUM-67 ISOTOPES, BY REGION,
2013-2020 ($MILLION) 54
TABLE 13 GLOBAL SPECT MARKET SIZE FOR IODINE-123 ISOTOPES, BY REGION,
2013-2020 ($MILLION) 55
TABLE 14 GLOBAL SPECT MARKET SIZE FOR OTHER ISOTOPES, BY REGION,
2013-2020 ($MILLION) 56
TABLE 15 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET ISOTOPES, BY REGION, 2013-2020 ($MILLION) 57
TABLE 16 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY ISOTOPE, 2013-2020 ($MILLION) 57
TABLE 17 GLOBAL PET MARKET SIZE FOR FLUORINE-18 ISOTOPES, BY REGION,
2013-2020 ($MILLION) 58
TABLE 18 GLOBAL PET MARKET SIZE FOR RUBIDIUM-82 ISOTOPES, BY REGION,
2013-2020 ($MILLION) 59
TABLE 19 GLOBAL PET ISOTOPES MARKET SIZE FOR OTHER ISOTOPES, BY REGION,
2013-2020 ($MILLION) 60
TABLE 20 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC ISOTOPES, BY REGION, 2013-2020 ($MILLION) 61
TABLE 21 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC ISOTOPES, BY TYPE, 2013-2020 ($MILLION) 61
TABLE 22 GLOBAL BETA EMITTERS MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 63
TABLE 23 GLOBAL BETA EMITTERS MARKET SIZE, BY ISOTOPE, 2013-2020 ($MILLION) 63
TABLE 24 GLOBAL BETA EMITTERS MARKET SIZE FOR IODINE-131 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 64
TABLE 25 GLOBAL BETA EMITTERS MARKET SIZE FOR YTTRIUM-90 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 65
TABLE 26 GLOBAL BETA EMITTERS MARKET SIZE FOR SAMARIUM-153 ISOTOPES,
BY REGION, 2013-2020 ($MILLION) 66
TABLE 27 GLOBAL BETA EMITTERS MARKET SIZE FOR RHENIUM-186 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 66
TABLE 28 GLOBAL BETA EMITTERS MARKET SIZE FOR LUTETIUM-177 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 67
TABLE 29 GLOBAL BETA EMITTERS MARKET SIZE FOR OTHER ISOTOPES, BY REGION,
2013-2020 ($MILLION) 68
TABLE 30 GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 69
TABLE 31 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY REGION, 2013-2020 ($MILLION) 71
TABLE 32 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY ISOTOPES, 2013-2020 ($MILLION) 71
TABLE 33 GLOBAL BRACHYTHERAPY MARKET SIZE FOR CESIUM-131 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 72
TABLE 34 GLOBAL BRACHYTHERAPY MARKET SIZE FOR IODINE-125 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 73
TABLE 35 GLOBAL BRACHYTHERAPY MARKET SIZE FOR PALLADIUM-103 ISOTOPES,
BY REGION, 2013-2020 ($MILLION) 73
TABLE 36 GLOBAL BRACHYTHERAPY MARKET SIZE FOR IRIDIUM-192 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 74
TABLE 37 GLOBAL BRACHYTHERAPY MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION) 75
TABLE 38 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE,
BY REGION, 2013–2020 (THOUSAND) 77
TABLE 39 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 78
TABLE 40 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 78
TABLE 41 NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 79
TABLE 42 NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 79
TABLE 43 NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 80
TABLE 44 NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 80
TABLE 45 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 81
TABLE 46 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 81
TABLE 47 NUCLEAR MEDICINE BETA EMITTERS PROCEDURE MARKET SIZE, BY TYPE,
2013–2020 (THOUSAND) 82
TABLE 48 NUCLEAR MEDICINE BETA EMITTERS PROCEDURE MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 82
TABLE 49 NUCLEAR MEDICINE ALPHA EMITTERS PROCEDURE MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 83
TABLE 50 NUCLEAR MEDICINE ALPHA EMITTERS PROCEDURE MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 83
TABLE 51 NUCLEAR MEDICINE BRACHYTHERAPY PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 84
TABLE 52 NUCLEAR MEDICINE BRACHYTHERAPY PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 84
TABLE 53 SEGMENTATION OF NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR SPECT APPLICATIONS, BY TYPE 87
TABLE 54 NUCLEAR MEDICINE/RADIOPHAMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 87
TABLE 55 NUCLEAR MEDICINE/RADIOPHAMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY TYPE, 2013-2020 ($MILLION) 88
TABLE 56 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 90
TABLE 57 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 91
TABLE 58 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 92
TABLE 59 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 93
TABLE 60 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 93
TABLE 61 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION OF PET, BY APPLICATION 94
TABLE 62 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 94
TABLE 63 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY TYPE, 2013-2020 ($MILLION) 95
TABLE 64 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ONCOLOGY PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 97
TABLE 65 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 97
TABLE 66 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 98
TABLE 67 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 99
TABLE 68 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 100
TABLE 69 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2013–2020($MILLION) 101
TABLE 70 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 103
TABLE 71 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BONE METASTASIS THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 104
TABLE 72 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 104
TABLE 73 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ENDOCRINE TUMOR THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 105
TABLE 74 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 106
TABLE 75 GLOBAL NUCLEAR MEDICINE /RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 108
TABLE 76 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 112
TABLE 77 NORTH AMERICA: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 112
TABLE 78 NORTH AMERICA: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 113
TABLE 79 NORTH AMERICA: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 113
TABLE 80 NORTH AMERICA: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 114
TABLE 81 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 116
TABLE 82 EUROPE: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013-2020 ($MILLION) 116
TABLE 83 EUROPE: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013-2020 ($MILLION) 117
TABLE 84 EUROPE: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE,
BY APPLICATION, 2013-2020 ($MILLION) 117
TABLE 85 EUROPE: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE,
BY APPLICATION, 2013-2020 ($MILLION) 118
TABLE 86 ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 121
TABLE 87 ASIA-PACIFIC: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 121
TABLE 88 ASIA-PACIFIC: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 122
TABLE 89 ASIA-PACIFIC: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 122
TABLE 90 ASIA-PACIFIC: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 123
TABLE 91 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 125
TABLE 92 ROW: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013-2020 ($MILLION) 126
TABLE 93 ROW: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013-2020 ($MILLION) 126
TABLE 94 ROW: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE,
BY APPLICATION, 2013-2020 ($MILLION) 127
TABLE 95 ROW: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE,
BY APPLICATION, 2013-2020 ($MILLION) 127
TABLE 96 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 131
TABLE 97 NORTH AMERICA: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 132
TABLE 98 NORTH AMERICA: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 132
TABLE 99 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 133
TABLE 100 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 135
TABLE 101 EUROPE: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE,
2013–2020 ($MILLION) 136
TABLE 102 EUROPE: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE,
2013–2020 ($MILLION) 136
TABLE 103 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 ($MILLION) 137
TABLE 104 ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 140
TABLE 105 ASIA-PACIFIC: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE,
2013–2020 ($MILLION) 140
TABLE 106 ASIA-PACIFIC: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 141
TABLE 107 ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 ($MILLION) 141
TABLE 108 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 143
TABLE 109 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL BETA EMITTERS MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 144
TABLE 110 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 144
TABLE 111 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 145
“
“LIST OF FIGURES
FIGURE 1 NUCLEAR MEDICINE/RADIOPHARMACEUTICAL MARKET SEGMENTATION 19
FIGURE 2 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH METHODOLOGY STEPS 21
FIGURE 3 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 24
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 26
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 26
FIGURE 6 DATA TRIANGULATION METHODOLOGY 28
FIGURE 7 DIAGNOSTICS MARKET TO WITNESS HIGHEST GROWTH RATE FROM 2015
TO 2020 29
FIGURE 8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTICS MARKET SHARE, BY TYPE, 2015–2020 30
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 31
FIGURE 10 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS SPECT APPLICATIONS,
2015–2020 32
FIGURE 11 ADVANCES IN RADIOTRACERS TO PROPEL MARKET GROWTH 33
FIGURE 12 NORTH AMERICA DOMINATES THE SPECT NUCLEAR MEDICINE DIAGNOSTICS MARKET IN 2015 34
FIGURE 13 ASIA-PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 35
FIGURE 14 DIAGNOSTICS SEGMENT TO COMMAND THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD 36
FIGURE 15 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, CHALLENGES, & OPPORTUNITIES 38
FIGURE 16 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE 47
FIGURE 17 THERAPEUTIC SEGMENT TO GROW AT THE HIGHEST CAGR OF 10.5% 48
FIGURE 18 PET SEGMENT TO GROW AT THE HIGHEST CAGR OF 11.7% DURING THE
FORECAST PERIOD 50
FIGURE 19 ALPHA EMITTERS SEGMENT TO GROW AT THE HIGHEST CAGR OF 17.3% DURING THE FORECAST PERIOD 62
FIGURE 20 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 9.4% DURING THE FORECAST PERIOD 88
FIGURE 21 THE NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 8.4% DURING THE FORECAST PERIOD 89
FIGURE 22 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 13.1% DURING THE FORECAST PERIOD 95
FIGURE 23 THE NEUROLOGY APPLICATION SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR OF 12.9% DURING THE FORECAST PERIOD 96
FIGURE 24 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC APPLICATIONS MARKET SEGMENTATION, BY TYPE 100
FIGURE 25 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 12.2% DURING THE FORECAST PERIOD 101
FIGURE 26 THE ENDOCRINE TUMORS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR OF 11.3% DURING THE FORECAST PERIOD 102
FIGURE 27 NORTH AMERICA COMMANDS LARGEST SHARE OF THE GLOBAL NUCLEAR MEDICINE DIAGNOSTIC MARKET IN 2015 109
FIGURE 28 NORTH AMERICA IS LIKELY TO WITNESS A CAGR OF 8.1% DURING THE FORECAST PERIOD 110
FIGURE 29 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET TO GROW AT A CAGR OF 7.1% DURING THE FORECAST PERIOD 115
FIGURE 30 ASIA-PACIFIC IS LIKELY TO WITNESS A CAGR OF 10.1% DURING THE FORECAST PERIOD 119
FIGURE 31 ROW NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET IS LIKELY TO GROW AT A CAGR OF 9% IN THE FORCAST PERIOD 124
FIGURE 32 NORTH AMERICA IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE GLOBAL NUCLEAR MEDICINE THERAPEUTIC MARKET IN 2015 128
FIGURE 33 NORTH AMERICA TO WITNESS A CAGR OF 10% IN THE GLOBAL NUCLEAR MEDICINE THERAPEUTIC MARKET DURING THE FORECAST PERIOD 129
FIGURE 34 EUROPE IS LIKELY TO WITNESS A CAGR OF 9.8% DURING THE FORECAST PERIOD 134
FIGURE 35 ASIA-PACIFIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET TO GROW AT A CAGR OF 12.2% DURING THE FORECAST PERIOD 138
FIGURE 36 THE GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET IN ROW IS EXPECTED TO GROW AT A CAGR OF 8.7% DURING THE FORECAST PERIOD 142
FIGURE 37 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014 146
FIGURE 38 STRATEGIES ADOPTED BY KEY PLAYERS OVER THE LAST THREE YEARS
(2012-2015) 153
FIGURE 39 BATTLE FOR MARKET SHARE: AGREEMENTS/CONTRACTS/PARTNERSHIPS WAS THE KEY STRATEGY (2012 -2015) 154
FIGURE 40 AGREEMENTS, CONTRACTS, AND PARTNERSHIPS, 2012-2015 155
FIGURE 41 ACQUISITIONS, 2012-2015 155
FIGURE 42 MARKET DEVELOPMENT, 2012-2015 156
FIGURE 43 EXPANSIONS, 2012-2015 157
FIGURE 44 NEW PRODUCT LAUNCHES, 2012-2015 157
FIGURE 45 OTHER STRATEGIES, 2012-2015 158
FIGURE 46 GEOGRAPHICAL REVENUE MIX OF KEY PLAYERS IN THE MARKET 159
FIGURE 47 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT 160
FIGURE 48 MALLINCKRODT PLC: COMPANY SNAPSHOT 163
FIGURE 49 GE HEALTHCARE: COMPANY SNAPSHOT 165
FIGURE 50 LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT 168
FIGURE 51 BAYER HEALTHCARE: COMPANY SNAPSHOT 170
FIGURE 52 NORDION, INC.: COMPANY SNAPSHOT 176
FIGURE 53 ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT 178
“
